18112-31-7 Usage
Uses
Used in Pharmaceutical Research and Development:
6-chloro-2-Methyl-3-broMo-iMidazo[1,2-b]pyridazine is used as a key intermediate in the synthesis of pharmaceutical drugs due to its unique chemical structure and potential biological activities. Its presence of chloro, bromo, and methyl groups allows for further chemical modifications, enhancing its therapeutic properties.
Used in Medicinal Chemistry Studies:
In the field of medicinal chemistry, 6-chloro-2-Methyl-3-broMo-iMidazo[1,2-b]pyridazine is utilized as a valuable target for studying its potential use in the treatment of various diseases. Its chemical structure provides a foundation for understanding the compound's interactions with biological targets and its potential therapeutic effects.
Used in Drug Synthesis:
6-chloro-2-Methyl-3-broMo-iMidazo[1,2-b]pyridazine is employed as an important building block in the synthesis of various pharmaceutical drugs. Its unique structure and functional groups contribute to the development of new drugs with improved efficacy and safety profiles.
Used in the Treatment of Various Diseases:
6-chloro-2-Methyl-3-broMo-iMidazo[1,2-b]pyridazine is being studied for its potential use in the treatment of various diseases. Its biological activities and chemical properties make it a promising candidate for further research and development in the medical field.
Check Digit Verification of cas no
The CAS Registry Mumber 18112-31-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,1,1 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 18112-31:
(7*1)+(6*8)+(5*1)+(4*1)+(3*2)+(2*3)+(1*1)=77
77 % 10 = 7
So 18112-31-7 is a valid CAS Registry Number.
18112-31-7Relevant academic research and scientific papers
MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS
-
Paragraph 0266; 0269-0270, (2014/09/29)
Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of
Process for brominating ergot alkaloids
-
, (2008/06/13)
The present invention provides an improved process for the production of a compound of formula I STR1 wherein R1 is carboxyl, alkoxy(C1-5)carbonyl, amido, alkyl(C1-5)amido, di(alkyl(C1-5)amido or an amido radical of formula II STR2 wherein Ra is alkyl(C1-4), Rb is alkyl(C1-4) or benzyl, and R2 is hydrogen or alkyl(C1-4), and either R3 is hydrogen and R4 is hydrogen or alkoxy(C1-4) or R3 and R4 together are a single bond, characterized in that a compound of formula III STR3 wherein R1 to R4 are as defined above, is brominated with a bromine complex of 3-bromo-6-chloro-2-methyl-imidazo[1,2-b]pyridazine.
